Eiger BioPharmaceuticals, Inc.
EIGR
Hisse Senetlerindeki Sıralama
#36387
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Hisse Fiyatı
$1.73
Son senkronizasyon: 2025-06-17
Piyasa Değeri
$2.55M
Değişim (1 gün)
-0.29%
Değişim (1 yıl)
-79.71%
Ülke
US
Ticaret Eiger BioPharmaceuticals, Inc. (EIGR)
Kategori
Healthcare
Eiger BioPharmaceuticals, Inc. (EIGR) için hisse senedi fiyat geçmişi
Gün sonu en yüksek fiyat: $8.50 - 2024-10-01
Gün sonu en düşük fiyat: $3.75K - 2014-01-01
Gün sonu en düşük fiyat: $3.75K - 2014-01-01
Eiger BioPharmaceuticals, Inc. için hisse fiyatı geçmişi: 2014 - 2026
Yıllık Hisse Fiyatı Performansı
| Yıl | Performans |
|---|---|
| 2024 | 8.23% |
| 2023 | -86.28% |
| 2022 | -65.86% |
| 2021 | -43.34% |
| 2020 | -27.82% |
| 2019 | 28.55% |
| 2018 | -15.78% |
| 2017 | 8.44% |
| 2016 | -45.90% |
| 2015 | -91.44% |
| 2014 | 0.00% |
Benzer şirketler veya rakiplerin hisse fiyatı
| Şirket | Hisse fiyatı | Değişim 1yıl% | Ülke |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $757.00 | 7.59% |
CH
|
